{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T22:09:45Z","timestamp":1778191785198,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.pharma.2026.04.006","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T14:50:30Z","timestamp":1776783030000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacist-led multidisciplinary care and its clinical impact on haematology patients receiving intravenous immuno-chemotherapy"],"prefix":"10.1016","author":[{"given":"Marie-Anne","family":"Cerfon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chlo\u00e9","family":"Herledan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Albert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandine","family":"Baudouin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Sesques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reine","family":"Kimbidima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Golfier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herv\u00e9","family":"Ghesquieres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Rioufol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Ranchon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pharma.2026.04.006_bib0175","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharma.2026.04.006_bib0180","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-020-00900-7","article-title":"A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA","volume":"13","author":"Sehn","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"5","key":"10.1016\/j.pharma.2026.04.006_bib0185","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/j.seminhematol.2023.11.004","article-title":"Epidemiology and etiology of diffuse large B-cell lymphoma","volume":"60","author":"Wang","year":"2023","journal-title":"Semin Hematol"},{"issue":"9759","key":"10.1016\/j.pharma.2026.04.006_bib0190","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2026.04.006_bib0195","first-page":"18","article-title":"Interaction between complementary and alternative medicine with conventional anti-cancer medicine","volume":"35","author":"Clarke","year":"2011","journal-title":"Cancer Forum"},{"issue":"15","key":"10.1016\/j.pharma.2026.04.006_bib0200","doi-asserted-by":"crossref","first-page":"24401","DOI":"10.18632\/oncotarget.14224","article-title":"Use of Complementary and Alternative Medicine (CAM) in cancer patients: an Italian multicenter survey","volume":"8","author":"Berretta","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.pharma.2026.04.006_bib0205","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00432-021-03645-z","article-title":"Real-life drug-drug and herb-drug interactions in outpatients taking oral anticancer drugs: comparison with databases","volume":"148","author":"Prely","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"10.1016\/j.pharma.2026.04.006_bib0210","doi-asserted-by":"crossref","first-page":"e31321","DOI":"10.2196\/31321","article-title":"An integrated model to improve medication reconciliation in oncology: prospective interventional study","volume":"23","author":"Passardi","year":"2021","journal-title":"J Med Internet Res"},{"issue":"11","key":"10.1016\/j.pharma.2026.04.006_bib0215","doi-asserted-by":"crossref","first-page":"e674","DOI":"10.1200\/JOP.18.00085","article-title":"Collaborative physician-pharmacist-managed multiple myeloma clinic improves guideline adherence and prevents treatment delays","volume":"14","author":"Sweiss","year":"2018","journal-title":"J Oncol Pract"},{"issue":"9","key":"10.1016\/j.pharma.2026.04.006_bib0220","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1016\/j.clml.2020.04.012","article-title":"Impact of an oncology clinical pharmacist specialist in an outpatient multiple myeloma clinic","volume":"20","author":"Virani","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"10.1016\/j.pharma.2026.04.006_bib0225","doi-asserted-by":"crossref","first-page":"7905","DOI":"10.1007\/s00432-023-04630-4","article-title":"Clinical and economic impact of clinical oncology pharmacy in cancer patients receiving injectable anticancer treatments: a systematic review","volume":"149","author":"Lattard","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.pharma.2026.04.006_bib0230","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1177\/1078155212449031","article-title":"Clinical pharmacy services and research for lymphoma patients at a cancer center","volume":"19","author":"Chan","year":"2013","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"10.1016\/j.pharma.2026.04.006_bib0235","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1191\/1078155205jp156oa","article-title":"Pharmaceutical validation as a process of improving the quality of antineoplastic treatment","volume":"11","author":"Serrano Fabi\u00e1","year":"2005","journal-title":"J Oncol Pharm Pract"},{"issue":"18","key":"10.1016\/j.pharma.2026.04.006_bib0240","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1200\/JCO.20.03088","article-title":"The randomized AMBORA trial: impact of pharmacological\/pharmaceutical care on medication safety and patient-reported outcomes during treatment with new oral anticancer agents","volume":"39","author":"D\u00fcrr","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.pharma.2026.04.006_bib0245","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.3390\/cancers14102532","article-title":"Clinical and economic impact of a multidisciplinary follow-up program in lymphoma patients","volume":"14","author":"Devaux","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.pharma.2026.04.006_bib0250","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1743-7563.2012.01522.x","article-title":"Importance of health literacy in oncology","volume":"8","author":"Koay","year":"2012","journal-title":"Asia Pac J Clin Oncol"},{"issue":"4","key":"10.1016\/j.pharma.2026.04.006_bib0255","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/ejhpharm-2020-002642","article-title":"CLEO: a multidimensional tool to assess clinical, economic and organisational impacts of pharmacists\u2019 interventions","volume":"28","author":"Vo","year":"2021","journal-title":"Eur J Hosp Pharm"},{"issue":"1","key":"10.1016\/j.pharma.2026.04.006_bib0260","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41687-018-0027-8","article-title":"\u00ab\u00a0Ben\u00a0\u00bb, et al. Validation of the French version of the functional, communicative and critical health literacy scale (FCCHL)","volume":"2","author":"Ousseine","year":"2017","journal-title":"J Patient Rep Outcomes"},{"issue":"3","key":"10.1016\/j.pharma.2026.04.006_bib0265","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/1078155220976801","article-title":"Impact of clinical pharmacy in oncology and hematology centers: a systematic review","volume":"27","author":"Oliveira","year":"2021","journal-title":"J Oncol Pharm Pract"},{"issue":"6","key":"10.1016\/j.pharma.2026.04.006_bib0270","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1177\/1078155218786048","article-title":"The role of the pharmacist in the multidisciplinary approach to the prevention and resolution of drug-related problems in cancer chemotherapy","volume":"25","author":"Bo\u015fnak","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"7","key":"10.1016\/j.pharma.2026.04.006_bib0275","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1177\/1078155218807748","article-title":"Clinical oncology pharmacist: effective contribution to patient safety","volume":"25","author":"Duarte","year":"2019","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"10.1016\/j.pharma.2026.04.006_bib0280","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s40545-021-00379-8","article-title":"Importance of medication reconciliation in cancer patients","volume":"14","author":"Elbeddini","year":"2021","journal-title":"J Pharm Policy Pract"},{"issue":"8","key":"10.1016\/j.pharma.2026.04.006_bib0285","first-page":"3557","article-title":"Clinical and economic impact of medication reconciliation in cancer patients: a systematic review","volume":"28","author":"Herledan","year":"2020","journal-title":"Support Care Cancer"},{"issue":"3","key":"10.1016\/j.pharma.2026.04.006_bib0290","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1177\/1078155219861679","article-title":"Drug-related problems with targeted\/immunotherapies at an oncology outpatient clinic","volume":"26","author":"Kucuk","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"10.1016\/j.pharma.2026.04.006_bib0295","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1177\/1078155220915763","article-title":"Clinical and economic impact of pharmacist interventions in an ambulatory hematology-oncology department","volume":"26","author":"de\u00a0Gr\u00e9gori","year":"2020","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"10.1016\/j.pharma.2026.04.006_bib0300","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/s12885-024-12291-w","article-title":"Determination of drug-related problems in the hematology service: a prospective interventional study","volume":"24","author":"Albayrak","year":"2024","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.pharma.2026.04.006_bib0305","first-page":"1287","article-title":"The impact of medication therapy management in older oncology patients","volume":"21","author":"Yeoh","year":"2013","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.pharma.2026.04.006_bib0310","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12913-020-4963-7","article-title":"Clinical, economic and organizational impact of pharmacist interventions on injectable antineoplastic prescriptions: a prospective observational study","volume":"20","author":"Zecchini","year":"2020","journal-title":"BMC Health Serv Res"},{"issue":"5","key":"10.1016\/j.pharma.2026.04.006_bib0315","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s12199-013-0340-z","article-title":"The 14-item health literacy scale for Japanese adults (HLS-14)","volume":"18","author":"Suka","year":"2013","journal-title":"Environ Health Prev Med"},{"issue":"6","key":"10.1016\/j.pharma.2026.04.006_bib0320","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.sapharm.2015.12.003","article-title":"Don\u2019t assume the patient understands: qualitative analysis of the challenges low health literate patients face in the pharmacy","volume":"12","author":"Wali","year":"2016","journal-title":"Res Soc Adm Pharm"},{"issue":"11","key":"10.1016\/j.pharma.2026.04.006_bib0325","doi-asserted-by":"crossref","first-page":"e0259815","DOI":"10.1371\/journal.pone.0259815","article-title":"The role of health literacy in cancer care: a mixed studies systematic review","volume":"16","author":"Holden","year":"2021","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.pharma.2026.04.006_bib0330","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1002\/cncr.31733","article-title":"Health literacy and cancer self-management behaviors: a scoping review","volume":"124","author":"Papadakos","year":"2018","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.pharma.2026.04.006_bib0335","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.6004\/jnccn.2021.7029","article-title":"Health literacy in surgical oncology patients: an observational study at a comprehensive cancer center","volume":"19","author":"Rothermel","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.pharma.2026.04.006_bib0340","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/1078155216634180","article-title":"Evaluating the patient-perceived impact of clinical pharmacy services and proactive follow-up care in an ambulatory chemotherapy unit","volume":"23","author":"Crespo","year":"2017","journal-title":"J Oncol Pharm Pract"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450926000659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450926000659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T21:14:48Z","timestamp":1778188488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450926000659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":34,"alternative-id":["S0003450926000659"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2026.04.006","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacist-led multidisciplinary care and its clinical impact on haematology patients receiving intravenous immuno-chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2026.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}